Data Sheet (Cat.No.T27660)

TargetMol

JNJ-10311795

Chemical Properties



CAS No. : 518062-14-1

Formula: C40H35N2O6P

Molecular Weight: 670.69

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	JNJ-10311795 (RWJ-355871) is a potent dual inhibitor of neutrophil elastase (Ki = 38 nM) and mast cell chymase (Ki = 2.3 nM) with significant anti-inflammatory activity, useful for studying pneumonia.
Targets(IC50)	Cysteine Protease
In vitro	JNJ-10311795 is a novel effective dual inhibitor of neutrophil cathepsin G (K (i) = 38 nM, IC50 = 82 nM) and mast cell rennet (K (i) = 2.3 nM). [1]
In vivo	In a rat model of inflammation, JNJ-10311795 (0.5 mg/kg intravenously) was administered 30 minutes before glycogen therapy, followed by 10 mg/kg/h intravenous infusion for 4.5 hours (total dose = 45.5 mg/kg). The increase in myeloperoxidase was reduced by 50% (neutrophil counts were reduced by 50%). [1]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.491 mL	7.455 mL	14.910 mL
5 mM	0.2982 mL	1.491 mL	2.982 mL
10 mM	0.1491 mL	0.7455 mL	1.491 mL
50 mM	0.0298 mL	0.1491 mL	0.2982 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

de Garavilla L, et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem. 2005 May 6;280(18):18001-7.

Gater D, Macauley D. American Chemical Society--238th National Meeting & Exposition. Developments in medicinal chemistry: part 2. 16-20 August 2009, Washington DC, USA. IDrugs. 2009 Oct;12(10):608-11. PubMed PMID: 19790005.

Tausch L, Henkel A, Siemoneit U, Poeckel D, Kather N, Franke L, Hofmann B, Schneider G, Angioni C, Geisslinger G, Skarke C, Holtmeier W, Beckhaus T, Karas M, Jauch J, Werz O. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol. 2009 Sep 1;183(5):3433-42. doi: 10.4049/jimmunol.0803574. Epub 2009 Jul 31. PubMed PMID: 19648270.

de Garavilla L, Greco MN, Sukumar N, Chen ZW, Pineda AO, Mathews FS, Di Cera E, Giardino EC, Wells GI, Haertlein BJ, Kauffman JA, Corcoran TW, Derian CK, Eckardt AJ, Damiano BP, Andrade-Gordon P, Maryanoff BE. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem. 2005 May 6;280(18):18001-7. Epub 2005 Feb 28. PubMed PMID: 15741158.